Using Smartphones and Machine Learning to Quantify Parkinson Disease Severity:The Mobile Parkinson Disease Score by Zhan, Andong et al.
Using Smartphones andMachine Learning
to Quantify Parkinson Disease Severity
TheMobile Parkinson Disease Score
Andong Zhan, MS; Srihari Mohan; Christopher Tarolli, MD; Ruth B. Schneider, MD; Jamie L. Adams, MD;
Saloni Sharma, MD; Molly J. Elson, BA; Kelsey L. Spear, MPH; Alistair M. Glidden, BS; Max A. Little, PhD;
Andreas Terzis, PhD; E. Ray Dorsey, MD; Suchi Saria, PhD
IMPORTANCE Current Parkinson disease (PD) measures are subjective, rater-dependent, and
assessed in clinic. Smartphones canmeasure PD features, yet no smartphone-derived rating
score exists to assess motor symptom severity in real-world settings.
OBJECTIVES To develop an objective measure of PD severity and test construct validity by
evaluating the ability of themeasure to capture intraday symptom fluctuations, correlate
with current standard PD outcomemeasures, and respond to dopaminergic therapy.
DESIGN, SETTING, AND PARTICIPANTS This observational study assessed individuals with PD
who remotely completed 5 tasks (voice, finger tapping, gait, balance, and reaction time) on
the smartphone application. We used a novel machine-learning–based approach to generate
a mobile Parkinson disease score (mPDS) that objectively weighs features derived from each
smartphone activity (eg, stride length from the gait activity) and is scaled from0 to 100
(where higher scores indicate greater severity). Individuals with and without PD additionally
completed standard in-person assessments of PDwith smartphone assessments during a
period of 6months.
MAIN OUTCOMES ANDMEASURES Ability of themPDS to detect intraday symptom
fluctuations, the correlation between themPDS and standardmeasures, and the ability of the
mPDS to respond to dopaminergic medication.
RESULTS ThemPDSwas derived from 6148 smartphone activity assessments from 129
individuals (mean [SD] age, 58.7 [8.6] years; 56 [43.4%] women). Gait features contributed
most to the total mPDS (33.4%). In addition, 23 individuals with PD (mean [SD] age, 64.6
[11.5] years; 11 [48%] women) and 17 without PD (mean [SD] age 54.2 [16.5] years; 12 [71%]
women) completed in-clinic assessments. ThemPDS detected symptom fluctuations with a
mean (SD) intraday change of 13.9 (10.3) points on a scale of 0 to 100. Themeasure
correlated well with theMovement Disorder Society Unified Parkinson Disease’s Rating Scale
total (r = 0.81; P < .001) and part III only (r = 0.88; P < .001), the Timed Up and Go
assessment (r = 0.72; P = .002), and the Hoehn and Yahr stage (r = 0.91; P < .001). ThemPDS
improved by amean (SD) of 16.3 (5.6) points in response to dopaminergic therapy.
CONCLUSIONS AND RELEVANCE Using a novel machine-learning approach, we created and
demonstrated construct validity of an objective PD severity score derived from smartphone
assessments. This score complements standard PDmeasures by providing frequent,
objective, real-world assessments that could enhance clinical care and evaluation of novel
therapeutics.
JAMA Neurol. doi:10.1001/jamaneurol.2018.0809
Published online March 26, 2018.
Supplemental content
Author Affiliations:Author
affiliations are listed at the end of this
article.
Corresponding Author: Suchi Saria,
PhD, Malone Hall 333, Johns Hopkins
University, 3400N Charles St,
Baltimore, MD 21218
(ssaria@cs.jhu.edu).
Research
JAMANeurology | Brief Report
(Reprinted) E1
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a University of Bristol User  on 04/03/2018
C urrent Parkinson disease (PD) measures are subjec-tive and rater-dependent and require in-clinicassessments.1,2 As a result, clinical trials using these
measures are long, expensive, and can generate false
positives or negatives.2,3 Many motor symptoms of PD are
well-suited to objective measurement by smartphones.4-6
Smartphone assessment has been evaluated in PD, but most
studies focus on a specific feature (eg, gait), rather than
overall symptom burden.6,7 We developed an Android
smartphone application (named HopkinsPD) that assesses
5 activities (voice, finger tapping, gait, balance, and
reaction time; eMethods, eTable 1, and the eFigure in the
Supplement),8 which can be completed as often as desired
and includes reporting of medication administration. We
created a mobile Parkinson disease score (mPDS) to serve as
an objective measure of PD and tested construct validity by
evaluating the ability of the mPDS to detect intraday symp-
tom fluctuations, the correlation between this measure and
current standard PD measures, and the ability of the mPDS
to respond to dopaminergic therapy.
Methods
Study Population
IndividualswithPDwhoownedAndroidsmartphoneswere in-
vited to download HopkinsPD through the Parkinson Voice
Initiative.8Data fromparticipantswhocompletedat least 1com-
plete setofactivitiesbeforeandafter their firstdailydoseofdo-
paminergicmedication (development cohort)wereused tode-
velopthemPDS.Wealsorecruited individualswithandwithout
PD to complete smartphone activities alongside current stan-
dard assessments (clinic cohort); tests included theMovement
Disorder Society Unified Parkinson Disease’s Rating Scale
(MDS-UPDRS),9 theHoehnandYahr stage,10 and theTimedUp
and Go assessment11 at baseline, month 3, andmonth 6.
All study procedures were approved by the University of
Rochester research subjects review board. Development co-
hort participants provided electronic consent for data analy-
sis with application download. The clinic cohort participants
provided written informed consent.
Creating themPDS
Data from the development cohort were processed to extract
noveldisease features fromeachof the5activities (eg, the inter-
tap interval fromthe finger-tappingactivity).12Rather thanrep-
licating an existing PD score using regression,weused a rank-
based machine-learning algorithm, disease severity score
learning (DSSL),13 to derive an independent measure of PD
symptom severity: the mPDS, which is scaled from 0 to 100,
with high numbers reflecting greater symptom severity.
To weigh unique features, the algorithm exploits weak
supervision14 based on the assumption that symptom sever-
ity is higher immediately preceding dopaminergic medica-
tion administration comparedwith a point 1 hour aftermedi-
cationadministration.Givenmany suchpairs,DSSLestimates
a score by optimizing an objective function to correctly rank
as many pairs as possible. Further description of the method
canbe found in theeMethodsand theeEquation in theSupple-
ment. Open-source code for feature extraction and the DSSL
learning algorithm was made available at https://github.com
/dashan-emr/mpds.
OutcomeMeasures
Weevaluated theabilityof themPDS tocapture symptomvari-
abilitybyevaluating theaverage intradayrange inmPDSamong
home-performed assessments in those with PD in the clinic
cohort. Smartphone and current standard assessments com-
pletedwithin 2 hours of each otherwere used to compare the
mPDSwith current standardmeasures in individualswithPD.
Pearson correlation was calculated between the mPDS and
theMDS-UPDRS total score and part III–only subscore (which
examines motor signs of PD), the Timed Up and Go assess-
ment, and theHoehnandYahr stage.Pvalues associatedwith
the Pearson correlation of 1 rating scale vs anotherwere com-
puted from 2-tailed single-hypothesis tests with the null hy-
pothesis that these correlations are 0. The test statistic was
computed bymultiplying the estimated correlation (ρ) by the
square rootof (N−2)/(1−ρ2)andconformstoa tdistributionwith
n−2df (wheren is thenumberof cross-sectionalpoints). These
P values should be interpreted for each test as the probability
of anuncorrelated systemproducing a datasetwith a Pearson
correlation at least as extreme as the one observed.We evalu-
ated the ability of the mPDS to respond to dopaminergic
therapy in the clinic cohort by comparing the mPDS derived
during optional, clinic-performed, on-medication vs off-
medication evaluations of individuals. A 1-tailed Wilcoxon
signed-rank test was used to assess significance (α = .05).
Statistical analysis was performed with R, version 3.4.1
(RProject forStatisticalComputing) andPython,version2.7.10
(Python Software Foundation).
Results
Atotalof250 individualswithPDdownloadedHopkinsPD; 129
(51.6%) fulfilled requirements for thedevelopment cohort. An
additional 23 individuals with PD and 17 without PD consti-
tuted the clinic cohort. Baseline characteristics are shown in
Table 1. Briefly, participants ranged in age from a mean (SD)
of58.7 (8.6)years in thedevelopmentcohort to64.6 (11.5)years
Key Points
Question Can a smartphone be used to quantify Parkinson
disease motor symptom severity?
Findings In this study, a machine learning approach was able to
generate an objective severity score for Parkinson disease from
smartphone sensor data. The score captured intraday symptom
fluctuations, correlated strongly with current standard rating
scales, and detected response to dopaminergic therapy.
Meaning A smartphone-derived severity score for Parkinson
disease is feasible and provides an objective measure of motor
symptoms inside and outside the clinic that could be valuable for
clinical care and therapeutic development.
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and 54.2 (16.5) years in the clinic cohortwith andwithout PD,
respectively; 161 of 169 individuals (95.3%) in the develop-
ment and clinic cohorts combinedwerewhite. Thosewith PD
completed 58 in-clinic assessments (22 [96%] at baseline,
18 [78%] atmonth 3, and 18 [78%] atmonth 6); thosewithout
PD completed 37 assessments (17 [100%] at baseline, 8 [47%]
at month 3, and 12 [71%] at month 6).
Creating themPDS
During 6 months, development cohort participants per-
formed a mean (SD) of 48 (61) complete activity sets (range,
2-278). A total of 435unique featureswere extracted from the
5 smartphone tasks; of these, 8 features from the finger-
tapping activity, 3 fromthebalance activity, 3 fromthegait ac-
tivity, and 1 from the voice activity contributed most toward
mPDS generation (eTable 2 in the Supplement). The relative
weightingof features ingenerating themPDSwasgait (33.4%),
balance (23.2%), finger tapping (23.0%), voice (17.0%), and re-
action time (3.4%). The mean (SD) mPDS (across all assess-
ments) was 30.3 (15.0) in control participants; this was 47%
lower than in those with PD (mean [SD] score, 57.5 [16.9]).
Outcomes
During6months, clinic cohort participants performedamean
(SD) of 210 (323) complete activity sets (range, 2-996). The
mPDS detected a mean (SD) intraday change of 13.9 (10.3)
points among those with PD. The Figure, A depicts intraday
severity fluctuations.Themean (SD)MDS-UPDRSpart IV score
(which assesses motor complications) was 4.6 (4.3) points. A
total of 16 smartphone and standard assessment pairs met
criteria for analysis. Table 2 shows the correlation matrix be-
tween the MPDS and standard clinical measures. There was
good to excellent correlation between the mPDS and the
MDS-UPDRS total (r = 0.81, P < .001) and part III–only sub-
score (r = 0.88, P < .001), the Timed Up and Go test (r = 0.72,
P = .002), and the Hoehn and Yahr stage (r = 0.91, P < .001).
The Figure, B shows the ability of the mPDS to monitor
symptom severity more frequently than standard measures.
In addition, 7on-medicationvsoff-medicationpairs of assess-
ments in individuals with PD who were either taking or not
taking medication were performed in the clinic cohort. The
mPDS decreased by a mean (SD) of 16.3 (5.6) points in re-
sponse to dopaminergic therapy, with significant Wilcoxon
signed rank test (W, 28; P = .01). The MDS-UPDRS part
III–only subscore decreased by a mean (SD) of 10.4 (4.6)
in response to dopaminergic therapy.
Discussion
The mPDS is a novel measure that provides rapid, remote,
frequent, and objective assessment of PD symptom severity
on widely available smartphones. We demonstrated con-
struct validity by showing that the mPDS can capture intra-
day fluctuations characteristic of PD, correlate with current
standard PD measures, and respond to dopaminergic medi-
cation administration.
The mPDS is complementary to current standard PD
measures. First, assessments can be performed frequently
in real-world settings.15 Second, the score provides an objec-
tive measure of PD symptom severity, not impacted by
interrater variability.16 Third, the mPDS, unlike current
standard measures, objectively weighs activity features.
The MDS-UPDRS part III is biased toward tremor-
predominant disease,1 with only 5 of 33 items assessing
gait or balance. In contrast, 56.6% of mPDS items are
derived from gait or balance activities. Finally, unlike cur-
rent standard measures, which can take years and signifi-
cant resources to develop,1 the mPDS was generated quickly
from a relatively small number of participants using auto-
mated techniques that can account for noise in data col-
lected from multiple smartphone sensors and self-reported
medication administration.17 Combining smartphone data
with the machine-learning methods outlined here may also
provide opportunities for developing objective severity
measures in other neurological conditions.
Table 1. Baseline Characteristics
Characteristic
No. (%)
Smartphone
Users
(n = 250)
Development
Cohort
(n = 129)
Clinic Cohort
With Parkinson
Disease
(n = 23)
Clinic Cohort
Without Parkinson
Disease
(n = 17)
Demographic
Age, y, mean (SD) 57.2 (9.4) 58.7 (8.6) 64.6 (11.5) 54.2 (16.5)
Women 95 (38.0) 55 (42.6) 11 (48) 12 (71)
White race 225 (90.0) 123 (95.3) 22 (96) 16 (94)
Hispanic/Latino 15 (6.0) 9 (7.0) 0 (0) 0 (0)
College graduate 238 (95.2) 121 (93.7) 14 (61) 8 (47)
Using internet or email at home 250 (100) 129 (100) 21 (91) 17 (100)
Clinical
Time since diagnosis, y, mean (SD) 4.4 (4.9) 4.3 (4.4) 7.0 (4.1) N/A
Taking levodopa 96 97 90 N/A
MDS-UPDRS total score, mean (SD) NA NA 55.0 (26.5) 4.6 (4.6)
MDS-UPDRS III score, mean (SD) NA NA 26.9 (11.2) 1.2 (1.7)
Timed Up and Go Test, s, mean (SD) NA NA 11.2 (3.3) 8.1 (1.3)
Hoehn and Yahr score, stage, mean (SD) NA NA 2.1 (0.7) 0.0 (0.0)
Abbreviations:
MDS-UPDRS, Movement Disorder
Society Unified Parkinson Disease’s
Rating Scale; NA, not applicable.
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Limitations
This study has several limitations. Participants were gener-
ally white, college-educated, people who owned Android
smartphones and thus were not representative of the
broader PD population. Only 51.6% of those who down-
loaded the application met criteria for inclusion in the devel-
opment cohort. Additionally, the clinic cohort included only
7 assessments to evaluate the responsiveness of the mPDS to
dopaminergic therapy administration, and only 16 smart-
phone and in-person assessment pairs met criteria for the
correlation analysis. However, to our knowledge, this
represents one of the largest longitudinal smartphone
assessments of PD.
Conclusions
Furthervalidationof themPDS ina larger samplewithpatient-
relevant anchors is needed. New iterations of the application
forAndroidand iOSsmartphoneswill expandparticipationand
includeadditional featuresandfunctionality thatcouldprovide
new insights into PD.
Figure. Mobile Parkinson Disease Score Assessment During 6Months
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Table 2. CorrelationMatrix Between theMobile Parkinson Disease Score (mPDS)
and Standard Parkinson Disease OutcomeMeasures
Testa
mPDS,
r (P Value)
MDS-UPDRS
part III only,
r (P Value)
MDS-UPDRS
Total,
r (P Value)
Timed Up
and Go time,
r (P Value)
Hoehn and
Yahr stage,
r
mPDS 1.00
MDS-UPDRS part III–only subscore 0.88 (<.001) 1.00
MDS-UPDRS total 0.81 (<.001) 0.82 (<.001) 1.00
Timed Up and Go assessment 0.72 (.002) 0.74 (.002) 0.27 (.36) 1.00
Hoehn and Yahr stage 0.91 (<.001) 0.96 (<.001) 0.80 (<.001) 0.70 (.003) 1.00
Abbreviations: mPDS, Mobile
Parkinson disease score;
MDS-UPDRS, Movement Disorder
Society Unified Parkinson Disease’s
Rating Scale.
a These findings are based on 16
cross-sectional points that met the
criteria for analysis.
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